Indoor Air Quality Asthma Study: The Effect of Indoor Air Quality and Mitigation of Same on Persistent Asthma (IAQ)

January 4, 2024 updated by: Daniel Evans, MD, Dayton Children's Hospital

Indoor Air Quality Asthma Study: A Cooperative Study Between Coepland LP, Cairify, and Dayton Children's Hospital to Determine the Effect of Indoor Air Quality and Mitigation of Indoor Air Quality on Persistent Asthma

The primary objective is to determine whether continuous sensing, control and mitigation of home indoor air quality influences the frequency of asthma related symptoms, as measured by Serum IgE, Spirometry with exhaled Nitric Oxide, missed school and workdays, need for pharmacologic intervention (albuterol, oral steroids), frequency of sick visits to pulmonologist or primary care provider (PCP), urgent care / emergency department visits, and hospitalizations

Study Overview

Status

Active, not recruiting

Conditions

Detailed Description

Participants will be in the research study for approximately 2 years. There will be 11 visits to the clinic for monitoring of asthma symptoms and pulmonary function and 16 interval contacts with research staff made by either telephone or email to monitor asthma symptoms. There will also be 5 visits to participants' homes by technicians from Emerson Climate Technologies and/or an electrician in cooperation with Emerson. During these visits Emerson employees will assess participants' homes to determine if they qualify for the study and install study equipment to monitor air quality for the first half of the study and monitor and mitigate air quality for the second half of the study. At the end of the study, the technicians and/or electrician from Emerson will reset the study equipment or replace participants' original equipment, if that is their wish.

Participants will be enrolled in the research study for approximately 2 years. The first year, technicians from the study sponsor will install indoor air quality monitoring equipment in the participants' homes and information about the air quality in their home as well as baseline health and asthma information will be collected. This will be done through continuous sensing via an Atmocube air quality sensor, and a portable air quality sensor, the Atmotube. Beginning in the second half of the study, mitigation strategies of a smart home thermostat, the Sensi Touch Smart Thermostat, a smart bath fan control, the Enbrighten Z-wave Switch, and high quality furnace filter, 3M Filtrete MPR 2800 Ultrafine Particle Reduction Air Filter, will be employed. Information about the participants' asthma, health status, and air quality in the homes will continue to be collected.

Study Type

Interventional

Enrollment (Estimated)

10

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Ohio
      • Dayton, Ohio, United States, 45404
        • Dayton Childrens Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

Child aged 5.0-15.9 years at the time of informed consent with mild, moderate, or severe persistent asthma diagnosis. In addition, participants

  • Agree to attend visits as outlined by protocol
  • Agree to respond to Asthma Control Test (ACT) and asthma control questions as outlined in protocol by telephone call, text, or email.
  • Are willing to comply with asthma treatment plan prescribed by physician.
  • Are willing to practice an acceptable form of birth control to avoid pregnancy. Acceptable forms of birth control include: true abstinence, male or female condom with or without spermicide, female barrier contraception (such as diaphragm, cervical cap, or sponge) with spermicide, continuous use of an intrauterine device throughout the study, hormonal contraceptives (including oral, patch, implanted, or injected), if used consistently and correctly throughout the study.
  • Reside in single-family dwellings and must either be homeowners or have written permission from their landlords to participate in the study.

In order to participate in the study, homes of participants must

  • have working ducted forced air HVAC systems
  • a 4-wire thermostat that is determined by Emerson technician to be capable of communicating with Sensi Touch Smart Thermostat
  • a bathroom fan switch with neutral wire and wall plate, controlling a bathroom fan that is vented to the outdoors
  • access to the internet with a modem or router.
  • A smartphone capable of pairing with the Atmotube Pro wearable sensor

Exclusion Criteria:

  • Exclusion criteria: Age <5.0 or >15.9 years at the time of informed consent, inability to commit to being in the same home for the length of the study, and/or not meeting the above inclusion criteria.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Pre-mitigation
Information will be collected from participants about their health status and asthma symptoms. Information about the air quality inside the participants' homes will also be collected.
Experimental: Indoor Air Quality Mitigation
Indoor air quality mitigation strategies of a smart home thermostat, smart bath fan switch, and a high-quality furnace filter will be employed within the participants' homes. Information will continue to be collected about participants' health status and asthma symptoms as well as the air quality inside their homes.
Mitigation of indoor air quality with use of smart thermostat, smart bath fan control, and high quality furnace filters
Other Names:
  • Sensi Touch Smart Thermostat
  • Enbrighten Z-Wave Switch
  • 3M Filtrete MPR 2800 Ultrafine Particle Reduction Air Filters

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Asthma Control Test questionnaire
Time Frame: Through study completion, approximately 2 years
Monthly Asthma Control Test by History. Possible scores ranging from 0 (worst control)-27 (best control) for patients ages 6-11 or 0 (worst control)- 25 (best control) for patients ages 12-16.
Through study completion, approximately 2 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of asthma related visits to Primary Care Physician, Emergency Department or Urgent Care
Time Frame: Through study completion, approximately 2 years
Sick Visits due to asthma
Through study completion, approximately 2 years
Number of missed school and work days
Time Frame: Through study completion, approximately 2 years
Number of missed school and work days due to asthma symptoms
Through study completion, approximately 2 years
Frequency of asthma Medication Use
Time Frame: Through study completion, approximately 2 years
Use of asthma rescue inhaler and systemic steroids
Through study completion, approximately 2 years
Spirometry with exhaled nitric oxide
Time Frame: Weeks 1, 13, 25, 37, 49, 53, 65, 77, 89, 101, 105
measurement of Forced Expiratory Volume in 1 second measured quarterly
Weeks 1, 13, 25, 37, 49, 53, 65, 77, 89, 101, 105
Physical examination
Time Frame: Weeks 1, 13, 25, 37, 49, 53, 65, 77, 89, 101, 105
head, eyes, ears, nose, throat (HEENT), lungs, cardiovascular, abdominal, neurologic, and musculoskeletal exam by a licensed physician.
Weeks 1, 13, 25, 37, 49, 53, 65, 77, 89, 101, 105
Mini Paediatric Asthma Quality of Life Questionnaire (MiniPAQLQ)
Time Frame: Weeks 1, 49, 53, 105
Questionnaire assessing quality of life for patients with asthma. Possible scores range from 13 (worst quality of life)- 91 (best quality of life)
Weeks 1, 49, 53, 105
Concentration in serum of immunoglobulin E (IgE)
Time Frame: Weeks 1, 53, 105
blood test measuring IgE
Weeks 1, 53, 105
height
Time Frame: Weeks 1, 13, 25, 37, 49, 53, 65, 77, 89, 101, 105
standing height in centimeters without shoes
Weeks 1, 13, 25, 37, 49, 53, 65, 77, 89, 101, 105
weight
Time Frame: Weeks 1, 13, 25, 37, 49, 53, 65, 77, 89, 101, 105
weight in kilograms without shoes
Weeks 1, 13, 25, 37, 49, 53, 65, 77, 89, 101, 105
heart rate
Time Frame: Weeks 1, 13, 25, 37, 49, 53, 65, 77, 89, 101, 105
heart beats per minute
Weeks 1, 13, 25, 37, 49, 53, 65, 77, 89, 101, 105
respiratory rate
Time Frame: Weeks 1, 13, 25, 37, 49, 53, 65, 77, 89, 101, 105
number of breaths per one minute
Weeks 1, 13, 25, 37, 49, 53, 65, 77, 89, 101, 105
blood pressure
Time Frame: Weeks 1, 13, 25, 37, 49, 53, 65, 77, 89, 101, 105
systolic over diastolic blood pressure measured in mm/Hg
Weeks 1, 13, 25, 37, 49, 53, 65, 77, 89, 101, 105
oxygen saturation
Time Frame: Weeks 1, 13, 25, 37, 49, 53, 65, 77, 89, 101, 105
percent of hemoglobin saturated by oxygen in blood
Weeks 1, 13, 25, 37, 49, 53, 65, 77, 89, 101, 105

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Daniel A. Evans, MD, Dayton Children's Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 18, 2023

Primary Completion (Estimated)

August 31, 2025

Study Completion (Estimated)

January 12, 2026

Study Registration Dates

First Submitted

March 6, 2023

First Submitted That Met QC Criteria

April 24, 2023

First Posted (Actual)

May 6, 2023

Study Record Updates

Last Update Posted (Estimated)

January 8, 2024

Last Update Submitted That Met QC Criteria

January 4, 2024

Last Verified

July 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Persistent Asthma

Clinical Trials on Indoor Air Quality Mitigation

Subscribe